0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Growth Hormone Deficiency (GHD) -Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-350
Home | Market Reports | Health
Growth Hormone Deficiency Epidemiology Forecast to 2028

Growth Hormone Deficiency (GHD) -Epidemiology Forecast to 2028

Code: DELV-Epid-350
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Growth Hormone Deficiency (GHD)  - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Growth Hormone Deficiency (GHD)  epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Growth Hormone Deficiency (GHD)  Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Growth Hormone Deficiency (GHD)  in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Growth Hormone Deficiency (GHD)  outlook. It also includes the explanation of changing trends of epidemiology outlining the Growth Hormone Deficiency (GHD)  scenario.

Growth Hormone Deficiency (GHD)  Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Growth Hormone Deficiency (GHD)  thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Growth Hormone Deficiency (GHD)  explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Growth Hormone Deficiency (GHD)  Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Growth Hormone Deficiency (GHD) 

Key assessments
• Patient Segmentation in Growth Hormone Deficiency (GHD) 
• Growth Hormone Deficiency (GHD)  Risk & Burden
• Factors driving growth in a specific Growth Hormone Deficiency (GHD)  patient population

1. Report Introduction
2. Growth Hormone Deficiency (GHD)  Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Growth Hormone Deficiency (GHD)  in 2016
2.2. Patient Share Distribution of Growth Hormone Deficiency (GHD)  in 2028
3. Disease Background and Overview: Growth Hormone Deficiency (GHD) 
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Growth Hormone Deficiency (GHD)  in 7MM
4.3. Total Prevalent/ Incident Patient Population of Growth Hormone Deficiency (GHD)  in 7MM – By Countries
5. Epidemiology of Growth Hormone Deficiency (GHD)  by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD) 
5.1.3. Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  *
5.1.4. Sex- Specific Cases of the Growth Hormone Deficiency (GHD) *
5.1.5. Diagnosed Cases of the Growth Hormone Deficiency (GHD) 
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD) 
5.4.3. Sub-Type Specific cases of the Growth Hormone Deficiency (GHD) *
5.4.4. Sex- Specific Cases of the Growth Hormone Deficiency (GHD) *
5.4.5. Diagnosed Cases of the Growth Hormone Deficiency (GHD) 
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD) 
5.5.3. Sub-Type Specific cases of the Growth Hormone Deficiency (GHD) *
5.5.4. Sex- Specific Cases of the Growth Hormone Deficiency (GHD) *
5.5.5. Diagnosed Cases of the Growth Hormone Deficiency (GHD) 
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD) 
5.6.3. Sub-Type Specific cases of the Growth Hormone Deficiency (GHD) *
5.6.4. Sex- Specific Cases of the Growth Hormone Deficiency (GHD) *
5.6.5. Diagnosed Cases of the Growth Hormone Deficiency (GHD) 
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD) 
5.7.3. Sub-Type Specific cases of the Growth Hormone Deficiency (GHD) *
5.7.4. Sex- Specific Cases of the Growth Hormone Deficiency (GHD) *
5.7.5. Diagnosed Cases of the Growth Hormone Deficiency (GHD) 
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD) 
5.8.3. Sub-Type Specific cases of the Growth Hormone Deficiency (GHD) *
5.8.4. Sex- Specific Cases of the Growth Hormone Deficiency (GHD) *
5.8.5. Diagnosed Cases of the Growth Hormone Deficiency (GHD) 
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD) 
5.9.3. Sub-Type Specific cases of the Growth Hormone Deficiency (GHD) *
5.9.4. Sex- Specific Cases of the Growth Hormone Deficiency (GHD) *
5.9.5. Diagnosed Cases of the Growth Hormone Deficiency (GHD) 
6. Unmet Needs of the Growth Hormone Deficiency (GHD) 
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in 7MM
Table 2: Total Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in United States (2016-2028)*
Table 6: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in France (2016-2028)
Table 12: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in France (2016-2028) *
Table 13: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in France (2016-2028) *
Table 14: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in UK (2016-2028) *
Table 26: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in 7MM
Figure 2: Total Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in France (2016-2028) *
Figure 14: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Growth Hormone Deficiency (GHD)  in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Growth Hormone Deficiency (GHD)  in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Growth Hormone Deficiency (GHD)  in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Growth Hormone Deficiency (GHD)  in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Novocure

RELATED REPORTS

Global and Japan Collagen Powder Market Insights Forecast to 2027
Global and Japan Collagen Powder Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-0T3500
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global Rice Protein Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Rice Protein Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

In 2020 the global Rice Protein market size was US 133 million and it is expected to reach US 310.6 million by the end of 2027 with a CAGR of 12.9 during 20212027.Global Rice Protein Market Size Manufacturers Supply Chain Sales Channel and Clients 20212027.

120 Pages
Type: Report
Code: QYRE-Auto-9G2510
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global Cardiac Monitoring Products Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Cardiac Monitoring Products Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10A290
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global and United States Radiation Oncology Market Size Status and Forecast 2021 2027
Global and United States Radiation Oncology Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-18B3286
Mon Sep 27 00:00:00 UTC 2021

Add to Cart